<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36818">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01904721</url>
  </required_header>
  <id_info>
    <org_study_id>192024-084</org_study_id>
    <nct_id>NCT01904721</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia
      (AGA).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in Target Area Hair Count (TAHC)</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject Self Assessment in Alopecia (SSA) Score on a 7-Point Scale</measure>
    <time_frame>Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment (IGA) Score on a 7-Point Scale</measure>
    <time_frame>Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Panel Review (GPR) Score on a 7-Point Scale</measure>
    <time_frame>Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Target Area Hair Width (TAHW)</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Target Area Hair Darkness (TAHD)</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Alopecia</condition>
  <condition>Alopecia, Androgenetic</condition>
  <condition>Baldness</condition>
  <arm_group>
    <arm_group_label>Stage 1: Bimatoprost Solution 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on scalp daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Bimatoprost Solution 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2: Bimatoprost Solution 1 applied evenly onto pre-specified area on scalp daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Bimatoprost Solution 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on scalp daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Bimatoprost Solution 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2: Bimatoprost Solution 2 applied evenly onto pre-specified area on scalp daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Bimatoprost Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Stage 1: Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on scalp daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Bimatoprost Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Stage 2: Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on scalp daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost Solution 1</intervention_name>
    <description>Bimatoprost Solution 1 applied evenly onto pre-specified area on scalp daily for 28 days, or daily for 6 months.</description>
    <arm_group_label>Stage 1: Bimatoprost Solution 1</arm_group_label>
    <arm_group_label>Stage 2: Bimatoprost Solution 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost Solution 2</intervention_name>
    <description>Bimatoprost Solution 2 applied evenly onto pre-specified area on scalp daily for 28 days, or daily for 6 months.</description>
    <arm_group_label>Stage 1: Bimatoprost Solution 2</arm_group_label>
    <arm_group_label>Stage 2: Bimatoprost Solution 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost Vehicle</intervention_name>
    <description>Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on scalp daily for 28 days, or daily for 6 months.</description>
    <arm_group_label>Stage 1: Bimatoprost Vehicle</arm_group_label>
    <arm_group_label>Stage 2: Bimatoprost Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss
             for at least 1 year

          -  Willingness to maintain same hair style, length and hair color during study

          -  Willingness to have micro-dot-tattoo applied to scalp  (Stage 2 only)

        Exclusion Criteria:

          -  Drug or alcohol abuse within 12 months

          -  HIV positive

          -  Received hair transplants or had scalp reductions

          -  Use of hair weaves, hair extensions or wigs within 3 months

          -  Use of minoxidil (oral or topical) and/or low level light treatment &quot;combs&quot; for hair
             growth within the last 6 months, or expected use during the study

          -  Application of topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to
             scalp within 4 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>July 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Cloprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
